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ABSTRACT
Cachexia is very common among patients with advanced pancreatic cancer and is a
marker of poor prognosis. Weight loss in cachexia is due to both adipose and muscle
compartments, and sarcopenia (severe muscle depletion) is associated with worse outcomes.
Curcumin has shown a myriad of biological effects, including anti-cancer and antiinflammatory. The ability of curcumin to attenuate cachexia and muscle loss has been tested
in animal models, with conflicting results so far. The hypothesis of this study was that
patients with advanced pancreatic cancer treated with curcumin for two months have less fat
and muscle loss as compared to matched controls not treated with this compound. A
matched 1:2 case-control retrospective study was conducted with 22 patients with pancreatic
cancer who were treated with curcumin on a previous protocol and 44 untreated controls
with the same diagnosis matched by age, gender, time from advanced cancer, body mass
index, and number of prior therapies. Data was collected regarding oncologic treatment,
medication use, weights, heights, and survival. Body composition was determined by
computerized tomography analyses at two timepoints separated by 60±20 days. For treated
patients, the first image was at the beginning of treatment and for controls it was determined
by the matching time from advanced cancer. The evolution of body composition over time
was quantitatively analyzed comparing both groups. All patients lost weight both due to fat
and muscle losses, and patients treated with curcumin presented greater losses both in lean
adipose body mass. Use of medications, chemotherapy, age, time from advanced cancer,
baseline albumin, performance status, and number of prior therapies were not independently
correlated with changes in body composition variables. Patients treated with curcumin had
borderline shorter survival when compared with untreated patients. Sarcopenic treated
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patients had significantly shorter survival than non-sarcopenic counterparts, and sarcopenia
status was not associated with survival among the controls. Treated patients with shorter
survival showed a tendency to lose more lean and especially fat body mass as compared to
untreated patients, maybe suggesting an effect of curcumin on shifting weight loss towards
the end of life by impacting its mechanisms.
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CHAPTER 1 – Introduction to cancer cachexia

Statement of importance
The whole spectrum of abnormalities in the amount of body fat and muscle (body
composition) has been associated to cancer prevention, treatment outcomes, and survival.
Increased body weight (overweight and obesity) has been associated with predisposition for
several types of cancers such as endometrial, breast (in postmenopausal woman), colon,
kidney, and esophagus (1-3). On the other hand, loss of body mass (both fat and lean
contents), broadly termed “cancer cachexia” has been associated with worse outcomes such
as decreased survival in patients with pancreatic cancer, loss of physical strength, and poorer
response to therapy (4-7) . To date, there is no effective treatment for the loss of body mass
in cancer cachexia. Finding strategies to fight this condition will allow for better patient care
as it allows better outcomes of cancer treatment and increased quality of life.

Definition
The term cachexia comes from the Greek words kakós (bad) and hexis (condition, state)
(8). In broad terms, cachexia is defined by an involuntary weight loss accompanied by
various degrees of associated factors such as anorexia, decline in muscular strength, and
inflammation (9). Recently, a specific definition of cancer cachexia has been suggested and
states that it is “a multi-factorial syndrome defined by an ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully reversed by conventional
nutritional support and leads to progressive functional impairment. The pathophysiology is
characterized by a negative protein and energy balance driven by a variable combination of
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reduced food intake and abnormal metabolism.” (10). Clinically, a patient is considered to
have cancer cachexia in the presence of weight loss greater than 5% in the past 6 months (if
simple starvation can be excluded) or any weight loss greater than 2% if the patient has a
BMI lower than 20 kg/m2. Additionally, a patient can be diagnosed with cachexia if a weight
loss greater than 2% is present combined with sarcopenia (defined as an appendicular
skeletal muscle index lower than 7.26 kg/m2 for males and 5.45 kg/m2 for females) (10).

Epidemiology
Overall, half of all patients with cancer lose some weight in the course of their diseases
(11). However, the prevalence of weight loss in patients with cancer is highly variable, and
it is significantly more frequent among patients with solid tumors, in which up to 80% have
weight loss of at least 5% of the premorbid body weight (5). In the last weeks of life, the
prevalence of weight loss in patients with cancer has been described as 86% (12), and
around 20% of all cancer deaths are directly related to cachexia (11).
In patients with pancreatic cancer, a 10% weight loss in comparison with premorbid
weight is present in approximately 80% of all cases, and at least 25% of these cases
presented cancer cachexia (6).

Pathophysiology
Cancer cachexia is multi-factorial and usually understood as having two major groups
of causal factors. One group encompasses the effect of the tumor and the body’s responses
to its presence, and is usually referred to as “primary cachexia”. The other group comprises
a myriad of conditions that can co-occur and affect energy intake (such as nausea, stomatitis,
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taste abnormalities, cognitive impairment, bowel obstruction, dental problems, for example),
protein balance (ageing, concomitant corticosteroid use, ascitis/pleural effusion repeat
drainage, for example), and induce catabolic states (such as infections, heart failure,
hypothyroidism, for example) (Figure 1) (13). The pathophysiology of primary cachexia will
be discussed here, and it is best understood by taking into account energy balance, muscle
and fat metabolism, and the influence of inflammation on catabolism.

Secondary causes

Comorbidities

Cancer

Cancer treatments

↓ food intake
Nausea/vomiting
Autonomic failure
Xerostomia
Mucositis
Dysphagia
Delirium
Uncontrolled symptoms
Constipation/bowel obstruction

Insulin
resistance

Tumor
byproducts

Anorexia

Inflammation

Hypogonadism

↓ protein/muscle
Deconditioning
Hypogonadism (other causes)
Aging
Nephrotic syndrome
Repeated paracentesis

↑catabolism
Infections
CHF, Renal failure, COPD,
Liver failure
Hyperthyroidism
Diabetes

Fat loss

Muscle loss

FIGURE 1 – Schematic representation of the mechanisms of cancer cachexia.

Energy balance and appetite regulation
Body weight is maintained relatively constant in healthy individuals when the energy
balance is kept neutral. In other words, energy expenditure and energy intake are equivalent
(14). In animal models, it has been proven that this equilibrium is tightly maintained by
coordinated mechanisms: in times of low energy availability, oxygen consumption is
3

lowered, and when energy supply is abundant, basal metabolism and energy expenditure
increase (15). Energy (food) intake is controlled by a hypothalamic system which integrates
several afferent signals from organs such as the gastrointestinal tract, the liver, and adipose
tissue (16).
The central hypothalamic integrative system is located adjacent to the third ventricle in
the arcuate nucleus and is composed of two neuronal populations: the orexigenic pathway
(which promotes food intake and reduces energy loss) and the anorexigenic pathway (which
in turn inhibits food intake and promotes energy use) (16). The orexigenic pathway neurons
express neuropeptide Y (NPY) and the agouti-related protein (AgRP) whereas the
anorexigenic pathway neurons express pro-opiomelanocortin (POMC) and cocaineamphetamine-related transcript (CART) (16). The message integrated in hypothalamus is
relayed to several effector neuron populations, most importantly: (a) the melaninconcentrating hormone (MCH) and the orexin/hypocretin neurons, which have downstream
orexigenic effect, ultimately leading to an increase in food intake (17-22); (b) neurons
expressing thyrotrophin-releasing hormone (TRH), which ultimately exert an anorexigenic
effect (23, 24); and (c) neurons secreting γ-aminobutyric acid (GABA), capable of
modulation of both orexigenic and anorexigenic pathways (25, 26).
The afferent signals to the hypothalamic integrative center come from several organs
via different pathways. Ghrelin, for example, is mostly produced in the stomach in response
to fasting, but also produced in smaller amounts by other organs (27), and exerts an
orexigenic effect both by activating NPY/AgRP neurons and inhibiting POMC/CART
neurons in the hypothalamic integrative center (27, 28). One group of specific afferent
signals “inform” the hypothalamus about the adiposity status of the body. Leptin is an
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important afferent adiposity signal arising from the adipocytes in response to the amount of
energy stored (greater energy storage amounts are linked to increased leptin levels), with
direct excitation of POMC/CART neurons and inhibition of NPY/AgRP neurons, decreasing
food intake and increasing the metabolic rate (16, 29, 30). Another adipositiy-related signal
is conveyed by insulin, which is secreted by the pancreas in response to adiposity and also
has inhibitory action over NPY/AgRP neurons and excitatory action over POMC/CART
neurons (31, 32).
The energy signals, another group of afferent signals, are responsible for “informing”
the hypothalamus about the energy status of the organism. The most important of those
signals is conveyed by the differential concentration of malonyl coenzyme A (malonyl-CoA)
in the hypothalamus, which increases in the presence of abundant fatty acids (signaling to
reduce appetite) and decreases when fatty acid concentration is low (signaling to increase
appetite) (33). Another energy signal comes from specialized cells sitting mainly in the
ileum and colon (L cells). Such cells respond to the presence of food and specifically its
caloric content by proportionately secreting peptide YY which has inhibitory action on
NPY/AgRP neurons, therefore with an anorexigenic effect (34, 35).
Pathogenesis of cancer anorexia
The pathogenesis of cancer anorexia is yet to be completely understood. Nevertheless,
evidence both from cancer animal models and from clinical studies point to several
derangements within the complex machinery that regulates energy intake. Several studies
failed to show a direct involvement of leptin (36, 37) and ghrelin (38, 39) in the genesis of
cancer anorexia, pointing towards a more central (hypothalamic) issue. There is evidence,
for example, showing that in the tumor-bearing state, brain neurochemistry can be changed
5

in specific brain areas, including the hypothalamus (40). Another argument favoring the
hypothesis of a hypothalamic derangement comes from research with NPY. It has been
shown that in anorexic tumor-bearing rats there is a significant decrease in NPY
imunorreactive neurons in the hypothalamus, suggesting that this might be part of the
genesis of anorexia in those animals (41). There is also evidence pointing towards the
impairment of the anorexigenic pathway in cancer anorexia. It has been shown that in
anorexic tumor-bearing rats in which POMC/CART neurons were inactivated the food
seeking behavior is restored (42, 43) and that in melanocortin-4 (MCR4) knock-out mice (in
which the activation of the POMC/CART pathway is incomplete) tumor growth is not
accompanied by anorexia as expected (42). It seems that cytokines play a major role in this
hypothalamic derangement (44). For example, injections of mianserin (an antagonist of the
IL1 receptor) directly to the hypothalamus of tumor-bearing anorexic rats were able to
increase food intake (45). Also supporting this, it has been shown in an animal model of
prostate adenocarcinoma that anorexia is associated with a detectable increase of IL1β
mRNA (46).
The mechanisms through which cytokines directly affect the hypothalamic control of
energy intake have been widely studied, and evidence now shows that cytokines act on the
melanocortin system mostly through serotonin release in the hypothalamus (47).
Fenfluramine, a serotonin agonist, has been shown to increase the concentration of serotonin
in the hypothalamus, inducing anorexia by activating POMC/CART neurons (48). Also, it
has been shown that in anorexic tumor-bearing rats the levels of hypothalamic serotonin are
significantly higher than those of normal rats, and when the cancer is removed, the serotonin
levels return to those of normal rats (49). In the clinical setting, the findings from animal
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models were confirmed by quantification of tryptophan (serotonin precursor) in the
cerebrospinal fluid of anorectic patients with cancer. These patients presented significantly
higher levels of free tryptophan when compared to healthy volunteers or non-anorectic
cancer patients (50). In addition, the same group was able to show that when the tumor is
removed, the tryptophan levels return to premorbid levels (51).

Adipose tissue metabolism in cancer cachexia
Adipose tissue is the largest energy reservoir in the human body. In healthy individuals,
adipose tissue stores triacylglicerol when energy balance is positive and releases nonsterified fatty acids when such balance is negative (52). Loss of adipose tissue is an
important feature of cancer cachexia. It has been shown by evaluation of cancer patients’
body composition by dual X-Ray absortiometry that the loss of adipose tissue precedes that
of skeletal muscle, and this was confirmed by computerized tomography analyses in a
different sample (53, 54). The major driver of lipid metabolism abnormalities in cancer
cachexia is a reduction in lipoprotein lipase activity, reducing the catabolism of triglycerides
and therefore impeding its accumulation in the adipocytes (55). This inhibition of
lipoprotein lipase occurs mainly as a result of direct action of cytokines such as IL2 (56) and
TNFα (57). The latter is also capable of increase lipolysis from the adipocytes themselves,
by inhibiting the adipose tissue hormone-sensitive lipase (58).
Another important player in the changes in adipose tissue of cachectic individuals is the
so-called Lipid Mobilizing Factor (LMF) which is a protein (zinc-α2-glycoprotein, ZAG)
identified in an animal model of cancer cachexia and found in the urine of cachectic
patients. ZAG is an adipokine produced by the adipose tissue which locally regulates fat
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mass and is overexpressed in several types of cancers (52). In vitro models show that ZAG
induces lipolysis in cultured adipocytes (52) and studies in animals demonstrated that ZAGinduced weight loss is specifically due to adipose tissue loss (59). In humans, it has been
shown that ZAG expression and concentration of mRNA is increased in the adipose tissue of
cachectic patients (52).

Muscle metabolism in cancer cachexia - Sarcopenia
As it is for energy, muscle metabolism is also mostly based on the balance between
protein synthesis and protein degradation (60). In the setting of cancer cachexia, both a
reduction in protein synthesis (hypoanabolism) and an increase in its degradation
(hypercatabolism) is observed (60, 61). To date, there is some debate on the importance of
each alteration (62), but most studies are focused in the hypercatabolism aspect.
Three major proteolytic systems are usually described: the lysossomal, the calcium
dependant, and the adenosine triphosphate- dependent ubiquitin-proteasome pathways (63).
In cancer cachexia, there is evidence of a preponderance of the latter, since in tumor-bearing
rats with increased proteolysis the inhibition of both lysossomal and calcium-dependant
pathways did not lead to reduction in proteolysis. Additionally, ubiquitin levels in the
atrophying muscles increased, therefore, the conclusion was that the ubiquitin-proteasome
pathway was the driving force behind muscle atrophy in this model (64).
In patients with cancer, the increased activity of the proteasome is believed to be caused
by several abnormalities such as increased oxidative stress, cytokines, and presence of the
tumor-secreted proteolysis inducing factor. Increased oxidative stress has been proven to
induce proteasome activity (65), and there is evidence that muscle wasting in animal models
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is not only induced by oxidative stress but also can be prevented by antioxidants (66). It is
believed that oxidative stress activates the expression of genes in the ubiquitin-proteasome
pathway through TNFα and NFκB activity (67).
Cytokines such as IL1, IL6, IFNγ, and TNFα have been shown to be involved in the
genesis of muscle atrophy in animal models of cachexia. TNFα administration caused an
increase in protein degradation with increase in proteasome gene expression and ubiquitin
levels (68). Innoculation of rats with cells that produce high levels of IFNγ caused severe
cachexia and also led to increased levels of ubiquitin (69).
A proteolysis-inducing factor (PIF) has been described initially in animal models as a
glycoprotein secreted by tumors (70) that increases protein degradation by increasing the
activity of the ubiquitin-proteasome pathway (71). The true existence of a human PIF
homologue has been debated. An independent group was unable to confirm its presence in
cancer cell lines (72) and this was rebutted with possible methodological issues as the
reason for the inability to detect PIF in such cases (73). Recently, a third independent
detected PIF in a sample of non-small cell lung cancer patients and reported its association
with survival and weight loss (74).

Trophic influence on skeletal muscle in cancer cachexia
Muscle hypoanabolism is tightly related to insulin resistance, hypogonadism, and
physical inactivity, issues frequently present in patients with cancer. In healthy individuals,
insulin exerts anabolic effects over the muscles. Muscle resistance to the anabolic effects of
insulin has been shown in a tumor-bearing rat model (75, 76). Resistance to the anabolic
effects of insulin has already been described in elderly, obese and diabetic adults. There is
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no definitive proof that cancer causes insulin resistance, however, since these conditions
frequently co-occur in patients with cancer, it is likely that insulin resistance plays a role in
the genesis of muscle wasting in cancer patients (77).
Physical activity is an important trophic factor for skeletal muscle, while inactivity
leads to muscle wasting. It has been shown in healthy elderly individuals that even a bed rest
as short as 10 days lead to a significantly increased tendency to muscle loss (78, 79). It is
likely that physical inactivity also plays a role in cancer cachexia, considering that cancer
patients tend to spend a significant amount of time in the hospital in the last year of life (80).
Hypogonadism has been reported as frequent in a sample of 47 male patients with
advanced cancer, with a prevalence of 81%. It impacts mood, fatigue, and more importantly,
cachexia/anorexia symptoms (81). At the level of the hypothalamus, hypogonadism might
be mediated by cytokines and drugs which lead to decreased gonadotrophin-releasing
hormone production. At the testicular level, testosterone reduction may be caused, in cancer
patients, by direct effect of chemotherapeutic drugs or by IL6. Opioid analgesics, megestrol
acetate, and corticosteroids are frequently used in patients with advanced cancer and are
concurrent causes of hypogonadism (77). Hypogonadism reduces an important anabolic
stimulus to skeletal muscle, leading to muscle depletion.

Inflammation
From the mechanisms described above, it is clear that inflammation plays a major role
in the genesis of primary cancer cachexia. Increase in inflammatory mediators can be
brought about by several factors in the patient with cancer: the tumor cells can generate
some amount of proinflammatory cytokines; the patient’s immune reaction (recruitment of
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immune cells to the tumor bed) brings up an increase in cytokine production; alterations in
the gastrointestinal tract; production of cytokines in the muscles and adipose tissue
themselves; and arise from secondary conditions such as infections (82).
The tumor environment is rich in inflammatory cytokines, some generated by the tumor
itself, and most generated by the host reaction to the tumor presence by recruitment of
macrophages to the tumor site. The presence of such cells in the tumor bed create a pool of
cytokines, chemokines, angiogenesis-promoting factors, reactive oxygen species (ROS),
matrix metalloproteinases, and prostanoids (83, 84) which only represent part of the greater
inflammatory process in the whole tumor-bearing host.
In the course of cancer treatment, and as a result of several chemotherapy regimens (85,
86), alterations in the integrity of the gastrointestinal tract lead to impairment of its barrier
function, allowing for the passage of bacterial endotoxins into the blood (87). The
endotoxins transported to the blood are a very potent stimulus for cytokine liberation by
mononuclear cells, and are considered to be a probable trigger for systemic inflammatory
response which drives cachexia (77).
Inflammatory drive in patients with cancer can be triggered by the presence of
concurrent chronic diseases. Patients with cancer usually are towards the 5th decade of life or
later, therefore at greater risk for chronic diseases such as cardiac failure, pulmonary
diseases, arthritis, and renal disease. In addition, patients with cancer are at greater risk for
infections. The presence of such comorbidities significantly increases the inflammatory
burden in cancer patients, contributing to the genesis of cancer cachexia (77).
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CHAPTER 2 – Curcumin

Origins and biochemistry
Curcumin is the phytochemical component responsible for the characteristic yellowgold color of turmeric (also known as Indian Curry) a spice used mostly in Asia. Found in
the root of the Curcuma longa plant, a member of the ginger family (Zingiberaceae),
turmeric is used not only as a condiment but also to treat several medical issues since around
1900 BC both in the Ayurvedic and Traditional Chinese medicines (88).
First isolated in 1815, curcumin had its structure determined as diferuloylmethane [1,7bis(4-hydroxy-3methoxyphenyl)-1,6-heptadiene-3,5-dione] in 1910. It is now known that in
addition to curcumin, two other curcumin analogues are found in turmeric:
demethoxycurcumin and bisdemethoxycurcumin. Even though there is evidence pointing
towards curcumin as the most effective among the three (89, 90), there is also some
evidence that bisdemethoxycurcumin might be most effective (91) and even that the
combination of the three analogues is what actually exerts the best action (92-94). Most
commercially available preparations have around three-fourths diferuloylmethane, one-fifth
demethoxycurcumin, and 5% bisdemethoxycurcumin.
Following oral administration, curcumin is metabolized into curcumin glucuronide and
curcumin sulfonate, while when administered intravenously, it is converted into
tetrahydrocurcumin, hexahydrocurcumin, and hexahydrocurcuminol. Curcumin is highly
hydrophobic and has very poor bioavailability because of its very low serum and tissue
levels, rapid metabolism, and rapid elimination (95). Efforts are underway to overcome this
issue, such as the development of a liposomal curcumin (96), the use of nanoparticles for
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curcumin delivery (97), the concomitant administration of adjuvants such as piperine (98),
insert structural modifications into the molecule (99), and the use of bioconjugates (100).

Actions and molecular targets
Several actions have been ascribed for curcumin: anti-inflammatory, antioxidant,
antiprotozoal, nematocidal, antibacterial, and anticancer, among others (101). Probably the
most widely studied action of this compound is the anti-inflammatory, which makes it an
interesting drug to be studied for the treatment of cancer cachexia.
Curcumin interacts with multiple molecular targets of interest for cancer cachexia
treatment. With regards to transcription factors, it has been shown that curcumin is capable
of inhibiting the activation of nuclear factor κB (NF-κB), peroxisome proliferator-activated
receptor γ (PPARγ), signal transducer and activator of transcription proteins (STAT), and β
catenin. Additionally, it also acts inhibiting the mitogen-activated protein kinase (MAPK)
pathway, paramount for inflammatory cascades (102).
In the oncology setting, curcumin has been widely studied for both treatment and
prevention of several types of cancers, because of is proven ability to inhibit cell
proliferation and invasion, to block angiogenesis, and to impair the progression of metastasis
(103). Of interest to this work, our group conducted a Phase II clinical trial in which a total
of 48 advanced pancreatic cancer patients received 8g of oral curcumin daily for the
investigation of its safety and antitumor activity. Objective responses were seen in two
patients: one had a short-lived marked tumor reduction of 73% followed by increases in
tumor size in subsequent re-evaluations and one had prolonged stable disease (greater than 8
months at publication which happened when accrual reached 25 patients) (104). Of note,
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curcumin was overwhelmingly very well tolerated, and no toxicities were observed by the
time of publication. In the treated patients, NF-κB, cyclooxygenase-2, and phosphorylated
signal transducer and activator of transcription 3 (STAT-3), which were higher than healthy
individuals at baseline, were reduced after treatment with curcumin, showing a potential
effect of the drug on these targets (104).

Curcumin and cachexia
The effects of curcumin in cachexia (specifically in muscle loss) have been studied by
several groups in animal models, yielding conflicting results. Busquets et al. studied the
antitumor and anticachectic effects of curcumin in a Wistar rat model innoculated with the
cachexia inducing Yoshida ascites hepatoma cells. Even though the investigators were able
to show a significant tumor reduction effect, no anticachectic effect was identified (105).
Another group, studying the effects of resveratrol and curcumin single-agent in a mice
model with implanted MAC16 colon tumor cells was able to observe attenuation in total
protein degradation with both drugs. In this model, however, curcumin was not able to
prevent weight loss and muscle protein degradation, and this was ascribed to its low
bioavailability (106). A third group studied the effects of curcumin on proteolysis and
muscle wasting both in vitro and in vivo (in a mice model with MAC16 colon tumor), and
was able to show a clear effect of weight loss reversal in mice treated with curcumin (107).
Other groups were able to show anticatabolic effects of curcumin in animal models of
sepsis, injury, and endotoxemia (108-110). To date, the effects of curcumin in cancer
cachexia were not studied in humans.
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CHAPTER 3 – RATIONALE, HYPOTHESIS, AND AIMS

Rationale
Cachexia is related to shorter survival and worse quality of life in patients with
advanced cancer. It is a multifactorial syndrome, in which loss of body weight (both fat and
muscle losses) is always present. Even though several mechanisms have been implicated in
its genesis, with inflammation playing a crucial role, there are very few evidence-based
strategies to date to face this problem. Curcumin has very potent anti-inflammatory
properties and therefore its impact on body composition is being studied in the current work.

Hypothesis
Patients with advanced pancreatic cancer treated with curcumin for two months have
less fat and muscle loss as compared to matched controls not treated with this compound.

Specific Aims
1. To determine the evolution of body tissue composition in patients with pancreatic
cancer treated with curcumin.
2. To determine whether there is a difference in body tissue composition over time
between patients with pancreatic cancer treated with curcumin and matched
untreated patients.
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CHAPTER 4 – METHODOLOGY

Patient population
The patient population for this retrospective observational study is composed of two
groups. The first group (treatment group) was obtained from a sample of patients with
advanced pancreatic cancer who participated on a clinical trial conducted at the
Investigational Cancer Therapeutics department at the University of Texas MD Anderson
Cancer Center between December/2004 and February/2006 (Protocol ID03-0009, Principal
Investigator Professor Razelle Kurzrock MD). These patients ingested daily eight one-gram
capsules containing 900mg of curcumin (90%), 80mg of desmethoxycurcumin (8%), and
20mg of bisdesmethoxycurcumin (2%) supplied by Sabinsa Corporation. The concentrations
of each of the curcuminoids contained in the capsules were confirmed by mass spectrometry
before the beginning of the trial (104). Forty-nine patients were treated on the clinical trial
and were considered for inclusion in the current study. The second group (control group) is
composed of patients with advanced pancreatic cancer treated at The University of Texas
MD Anderson Cancer Center between December/2004 and February/2006 who did not
receive curcumin.
The eligibility criteria for this study were expanded from the original clinical trial
(inclusion a-g and exclusion)(111) and were as follows:

Inclusion criteria
a. “The patient had pathologically confirmed adenocarcinoma of the pancreas
that was not amenable to curative surgical resection (includes locally
advanced, metastatic, or recurrent disease).
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b. The patient had a Karnofsky Performance Status of ≥ 60 at study entry.
c. The patient had ≥ 18 years of age.
d. The patient had adequate hematologic function as defined by an absolute
neutrophil count ≥ 1,500/mm2, platelet count ≥ 100,000/mm3.
e. The patient had adequate hepatic function as defined by a total bilirubin ≤ 2
X ULN, alkaline phosphatase, ALT and/or AST ≤ 5 X ULN, and creatinine ≤
2.0 mg/dL.
f. The patient had measurable disease.
g. The patient agreed to use effective contraception if procreative potential
exists (for enrollment on the original clinical trial)” (111)
h. The patient in the treatment group had one abdominal CT image including the L3
vertebra level 28±7 days before the first day of treatment (baseline image) and one
similar image within 60±20 days after the first day of treatment (follow up image).
i. The patient in the control group had two abdominal CT images including the L3
vertebra level separated by a range of 60±20 days. The number of days between the
first image and the diagnosis of advanced pancreatic cancer must be within 30 days
of the same difference for the matched treatment group patient.

Exclusion criteria
a. “The patient had a history of treated or active brain metastases,
carcinomatous meningitis, an uncontrolled seizure disorder, or active
neurological disease.
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b. The patient had received prior radiation. Patients with measurable disease
outside the radiation port or documented disease progression of previously
irradiated measurable disease were eligible. Patient must be ≥ 4 weeks posttherapy and have recovered from all toxicities.
c. The patient had an unstable medical condition according to the investigator,
including uncontrolled diabetes mellitus or hypertension; active infections
requiring systemic antibiotics, antivirals, or antifungals, unstable CHF,
uncontrolled arrhythmias, or unstable coagulation disorders.
d. The patient was pregnant or breast feeding.
e. The patient had received an investigational agent(s) within four weeks of
study entry.” (111)

Control matching procedure
Subjects in the control group were matched to those in the treatment group on a 1:2
matching ratio according to gender, age (within a range of ± 5 years), body mass index (± 5
kg/m2), Karnofsky performance status (± 20), number of prior therapies (± 2), and time
between first CT and advanced cancer diagnosis (± 3 months). Charts of all potential
controls were reviewed and data collected regarding the matching variables. All charts
received then a computer-generated random study accession number and the list of charts
was ascendantly sorted. The list was then searched from lowest to highest accession number
to find the first two adequate controls for each patient in the treatment group. This was done
by sequentially identifying matching gender, age, time from advanced cancer to baseline
image, body mass index, number of prior therapies, and performance status. On a first
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round, all controls who matched all variables were identified. Then, for patients with no
perfect matches available, variables were excluded from the matching procedure one by one
in reverse order to allow an even distribution of mismatches across the matching variables.
For example: the first variable not to be considered in the second matching round was
“performance status”. Therefore, remaining potential controls are searched for matches with
regards to the other five variables and the selected control is the one with the lowest
accession number that has performance status closest to the matching range. Once one
treated patient is matched to a control in this round, the match search for another patient
starts by excluding the variable “number of prior therapies” from the procedure and
matching all other five variables. Whenever another treated patient is matched to the control
with lowest accession number and closest “number of prior therapies” in this fashion, the
match search for a third patient starts, now excluding the variable “body mass index” and so
on.

Data collection
Basic demographic data, date of advanced pancreatic cancer diagnosis (defined as
locally advanced, recurrent, or metastatic), laboratory results, presence of ascitis and/or
edema, height, and weights were collected by chart review. Anticancer treatment history,
use of corticosteroids, progestins, androgens, and cannabinoids were also obtained from the
electronic charts.
Body mass indices (BMI) were calculated by dividing the weight (in kilograms) by the
height (in meters) squared (112). Patients were considered to be overweight or obese if they
had BMI ≥ 25.0 kg/m2 (113).
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Eligible abdominal CT images were identified by chart review and downloaded from
the institutional PACS (Picture Archiving and Communication System) network. In addition
to the baseline and follow up images described under “eligibility criteria”, one additional
image, 60±20 days before the baseline image, was downloaded for patients in whom it was
available (pre-baseline image).

Body composition determination by CT image analyses
The gold standard for determination of body composition is the dual X-Ray
absortiometry (DEXA), in which the different compartments of the body are determined by
the detection of the amount of radiation that is able to pass through different tissues (114).
However, it is not regularly clinically used in the population of patients with cancer. Indeed,
none of the patients treated with curcumin in the previous study had performed this
evaluation and therefore it was impossible to use this method for the purpose of this work.
Conversely, CT images are frequently obtained in the course of standard cancer care, and
provide direct view of the body fat and muscle compartments. In fact, it has been shown that
CT images are appropriate for body composition analyses in healthy populations (115, 116).
Mourtzakis et al have shown in cancer patients that quantification of the fat and muscle
contents found on a single abdominal CT slice at the level of the third lumbar vertebra (L3)
provide very adequate correlation with DEXA results (r = 0.82 and r = 0.89, for fat and fatfree masses, respectively, with p<0.001 for both correlations) (117).
Procedure
The evaluation of body composition by CT analysis is based on the fact that different
body tissues absorb different amounts of radiation, allowing their identification and
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quantification (118). The amount of radiation absorbed by a tissue is measured in
Hounsfield units (HU), in which the amount of X-ray energy absorbed by water is defined as
0 HU and then the percent absorption coefficient for bone is equivalent to 100 HU, and for
air is equivalent to -100 HU (119). It is known that skeletal muscle is characterized by a
range of -29 to 150 HU, subcutaneous and intramuscular adipose tissues by a range of -190
to -30 HU (120), and visceral adipose tissue by a range of -50 to -150 HU (121).

FIGURE 2 – CT image body composition determination procedure.

CT images are generated in a data format in which it is possible to determine the
amount of Hounsfield units per pixel (118). For this study, this determination was performed
by using Tomovision SliceOMatic computer software (Tomovision, Montreal, QC, Canada).
Abdominal CT images at L3 level were identified for all study subjects by chart review and
downloaded. Their identifiers were removed and the images were randomized for blinded
analysis. Each raw image was then loaded with the SliceOMatic software and the different
compartments (skeletal muscle and visceral, subcutaneous, and intramuscular adipose) were
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manually identified and marked according to their anatomical distribution and following the
described X-ray absorption coefficients (Figure 2). After completion of the identification of
the specified areas, the software calculates the area of each compartment, by multiplying the
number of pixels marked for each of them by the known area of each pixel.
A height-normalized muscle index is calculated by dividing the area of skeletal muscle
at L3 in centimeters squared by the height (in meters) squared (122). Patients were classified
as having sarcopenia (reduced muscularity) according to muscle index cutoffs previously
described of 52.4 cm2/m2 for men and 38.5 cm2/m2 for women (123).
The areas of skeletal muscle and fat were used to estimate the total body fat and lean
masses, according to the following formulae described by Mourtzakis et al (115):
and
), which have good correlation with DEXA measurements
(r=0.94, p<0.0001 and r=0.88, p<0.0001, respectively) (117).

Statistical analyses
Descriptive statistics were used to summarize the data. Continuous variables were
tested for normality using the Kolmogorov-Smirnov test. Means and standard errors of the
means were used for summarizing continuous variables with normal distribution, while
medians and ranges were used for summarizing continuous variables which did not follow a
normal distribution pattern. For consistency when presenting comparisons between variables
in which normality could not be assumed for all groups, medians and ranges were used to
summarize the data. Categorical variables were summarized by frequency. Differences in
categorical variables were tested for statistical significance by using the chi-squared or

22

Fisher exact tests, where appropriate. Differences in paired continuous variables were tested
by paired t-tests when the underlying distribution was normal and by the Wilcoxon ranksum test when not normally distributed. Statistical significance for differences between
independent continuous variables was evaluated by t-tests and Mann-Whitney tests
depending if normality was respectively assumed or not. Correlations were evaluated by
Pearson or Spearman coefficients, whenever appropriate also according with normality.
Survival analyses were conducted using Kaplan Meier plots with log-rank analyses. Patients
for whom date of death was not found were censored at the time of last follow up.
Differences were deemed to be statistically significant when the p values were less than or
equal to 0.05. All analyses were performed using SPSS v. 16 (SPSS Inc, Chicago, IL).
Selected graphs were composed using GraphPad Prism v. 5.04 (GraphPad Software, Inc., La
Jolla, CA).
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CHAPTER 5 – RESULTS

Study sample
Forty-nine patients were treated on protocol and were therefore considered for the
treatment group. Baseline images were available for all patients. However, 20/49 patients
(41%) were excluded because they did not have a follow up image. The reasons for lack of
images were: (a) patients died before restaging was performed (n=6/20, 30%), (b) patients
taken off study because of disease progression or clinical worsening (n=7/20, 35%), (c)
patients transferred to other services or lost to follow up (n=5/20, 25%), and (d) patients
were prematurely taken off study because of drug intolerance (n=2/20, 10%). Three
additional patients were excluded from the study sample because they had no suitable
images, and for four patients it was not possible to identify suitable controls. Reasons for
exclusion are summarized in Figure 3. As a result, 22 patients had two images meeting the
inclusion criteria and available controls, being included in the study group.
49 patients
Received curcumin on the previous protocol
20 (41%) no follow up image
6 (30%) died
7 (35%) off study (PD)
2 (10%) off study (SE)
5 (25%) transferred / lost to f/u

3 (6%) innappropriate images

4 (8%) no suitable control identified

22 patients
“Treatment group”

FIGURE 3 – Study population flowchart (PD=Progressive disease, SE=Side effects).
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The treatment group was composed by 10 women (45.5%) and 12 men (54.5%), with
median age 65.5 years (range 40-77). The median number of prior systemic therapies for
this group was 2 (range 0-6), and the median Karnofsky performance status was 80% (range
60%-100%).
Potential patients for the control group were pooled from all patients with pancreatic
cancer registered at the institution (excluded the 49 patients treated on the curcumin clinical
trial) who were seen between January/2005 and February/2006 (n=948). Of those, 399
(42%) patients were excluded because they have had only one abdominal CT performed
within the timeframe, being ineligible for the study. Of the remaining 549 patients, 309
(56%) had at least two images separated by 60±20 days, being selected to compose the pool
of patients potentially eligible for the control group. The two best matches for each patient
were selected to compose the control group, and the overall matched patient characteristics
are shown in Table 1. Median (IQR) time between baseline and follow up images was 63
(52-67.5) and 66 (59.75-75.25) days for patients in the treatment and control groups,
respectively (p=0.04).
Treatment
(N=22)
Female Gender (n, %)

10 (45.5%)

Control
(N=44)
20 (54.5%)

p value
1.000

Age (years) (mean, SEM)

63.8 (2.2)

63.2 (1.3)

0.823

Body Mass Index (mean, SEM)

23.8 (0.6)

24.1 (0.4)

0.707

2 (1-3)

2 (1-2)

0.237

7 (2-13.5)

6 (3-13.75)

0.749

Number of prior therapies
(median, IQR)
Time between advanced cancer and
baseline image (months)
(median, IQR)

TABLE 1 – Results of the matching process (SEM = standard error of the mean, IQR =
interquartile range).
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Body weight
Body weight and body mass index (BMI) data for patients without ascitis and/or edema
is summarized in Table 2 [ascitis and/or edema were present in 4/22 (18%) patients in the
treatment group and in 10/44 (23%) patients in the control group (p=0.759)]. The majority
of patients lost weight between baseline and follow up in both study groups, with a greater
frequency of weight losers in the treatment group [15/18 (83%) and 19/34 (56%) in the
treatment and control groups, respectively, p=0.07]. The absolute average weight loss in this
timeframe was somewhat greater in the treatment group [2.4 kg (SEM 0.8)] in comparison
with the control group [1.1 kg (SEM 0.6)], not reaching statistical significance (p=0.174).
The average percent weight loss was of 3.3% of the baseline weight for the treatment group
and 1.3% of the baseline weight for the control group, also not reaching statistical
significance (p=0.130) (Figure 4). Weight change was not different according to gender in
any of the groups.

Treatment

Baseline
Follow up
Variation

Weight (kg)
n (SEM)
P
69.4 (2.4)
0.007
67.0 (2.2)
-2.4 (0.8)
-.-

BMI (kg/m2)
n (SEM)
p
23.9 (0.5)
0.006
23.1 (0.5)
-0.8 (0.3)
-.-

Control

Baseline
Follow up
Variation

69.0 (2.2)
67.9 (2.0)
-1.1 (0.6)

24.0 (0.5)
23.6 (0.4)
-0.4 (0.2)

0.05
0.175*

0.05
0.160*

* p values for the comparison between the variations in the Treatment and Control groups.
TABLE 2 – Weight and BMI values for patients in both study groups at the 2 time points.
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100%
100

98.7%

p=0.130
96.7%

% of baseline weight

95

90

85

80

75

70

Control
Treatment
0
Baseline

Follow up

FIGURE 4 – Percent weight change in the study groups. (Whiskers represent the SEM)

According to usual BMI cutoffs, 6/18 (33%) treated patients and 12/34 (35%) controls
were considered to be overweight or obese at baseline (p=1.000) and 4/18 (22%) and 11/34
(32%) were classified as overweight or obese at follow up (p=0.532).

Body composition
All body composition parameters decreased in both groups between baseline and follow
up. The evolution of body composition variables is summarized in Table 3. No significant
differences were found with regards to such variables between patients in the treatment and
control groups at baseline. At follow up, the treatment group showed a trend towards lower
subcutaneous fat area at L3, total adipose area at L3 and total estimated body fat.
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Treatment
N=22
Median (IQR)
Skeletal muscle
area at L3 (cm2)
Muscle index
(cm2/m2)

119.7

(104-145.7)

Baseline
Controls
N=44
Median
(IQR)

p

Treatment
N=22
Median
(IQR)

Follow up
Controls
N=44
Median
(IQR)

p

125.1

(108-146.7)

0.661

112.5**

(95.6-137.5)

122.6

(102-149)

0.202

(37.6-47.4)

0.747

40.2**

(35.6-45.4)

41.6

(37.5-46.8)

0.115

(5.4-11)

0.833

7.7

(2.5-10.5)

7.0

(4.9-13)

0.430

(26.2-101)

68.5*

(35.7-104)

0.286

42.3

(37-46.7)

42.3

Intramuscular
adipose area at
L3 (cm2)

7.5

(3.4-12)

7.9

Visceral adipose
area at L3 (cm2)

57.3

(36.4-133.2)

73.4

(44.7-116.6)

0.668

42.3*

95

(65.7-191.9)

120

(101.6-172.7)

0.331

72.7**

(59.9-160.5)

116.7*

(84.6-149.2)

0.054

208.9

(119-317.5)

228.4

(147.3-294.8)

0.732

137.8**

(85.8-266.8)

217.8*

(154.2-282.9)

0.07

42

(37.3-49.8)

43.6

(38.5-50.1)

0.661

39.8**

(34.7-47.3)

42.8

(36.7-50.8)

0.202

20

(16.2-24.5)

20.8

(18.5-23.6)

0.732

17**

(14.8-22.4)

20.4*

(17.7-23.1)

0.07

Subcutaneous
adipose area at
L3 (cm2)
Total adipose
area at L3 (cm2)
Estimated total
lean body mass
(kg)
Estimated total
fat body mass
(kg)

* statistically significant differences between baseline and follow up time points within study groups. (* p < 0.05; ** p<0.001)
TABLE 3 –Body composition variables in both groups at baseline and follow up. (IQR = interquartile range).

28

Percent variation in body composition variables according to study groups are shown in
Figure 5. Patients in the treatment group showed greater percent reduction in all parameters
when compared to those in the control group. Significantly different reductions were
observed for skeletal muscle area at L3, intramuscular adipose area at L3, total adipose area
at L3, estimated total adipose body mass, and estimated total lean body mass. The median
percent change in estimated total lean body mass and total adipose body mass was
significantly greater for treated [-4.8% (IQR -9.1 to -0.1) and -6.8% (IQR -15 to -0.6),
respectively] than for untreated patients [-0.05% (IQR -4.2 to 2.6) and -4.0% (IQR -7.6 to
1.3), respectively] (p<0.001 and p=0.04 for lean and fat body mass changes, respectively).
The difference in percent changes for estimated total lean and adipose body masses was not
statistically different among curcumin treated patients, but was significantly different among
the controls, with the fat loss being greater (p=0.03).
Sarcopenia was present in 15/22 (68%) treated patients and 27/44 (61%) controls at
baseline (p=0.787). At follow up, sarcopenia was present in 18/22 (82%) treated patients and
29/44 (66%) controls (p=0.252). Sarcopenia combined with overweight or obesity (BMI ≥
25kg/m2) occurred in 3/18 (17%) and 5/34 (15%) treated and untreated patients at baseline,
respectively (p=0.574) and in 3/18 (17%) and 3/34 (9%) treated and untreated patients at
follow up, respectively (p=0.339). Male patients in the treatment group had a significantly
greater frequency of sarcopenia as compared to female patients in the same group
[11/12(92%) versus 4/10(40%) at baseline and 12/12 (100%) versus 6/10 (60%) at follow up
(p=0.020 and 0.029, respectively)]. In the control group, the frequency of sarcopenia in
males was also greater, however did not attain statistical significance in any of the
timepoints. No baseline sarcopenic patients reversed their low muscularity status at follow
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up. However, five patients developed sarcopenia at follow up (2 women and 1 man in the
treatment group and 2 women in the control group).
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100%
100%

100

99.3%

% of baseline intramuscular adipose area at L3

100

% of baseline skeletal muscle area at L3
or muscle index

p<0.001
95

94%

90

85

80

75

Skeletal muscle
area at L3

70

Control

98.4%
95

p=0.352
90.3%

90

85

80

75

Intramuscular adipose
area at L3

70

Control

Treatment

Treatment

0

0
Baseline

Follow up

Baseline

100%

100%
100

% of baseline intramuscular adipose area at L3

% of baseline visceral adipose area at L3

100
96.3%
95

p=0.426
91.8%

90

85

80

75

Follow up

Visceral adipose
area at L3

70

Control

95.9%

95

90

p=0.004
85

80
79.4%
75

Subcutaneous adipose
area at L3

70

Control

Treatment

Treatment

0

0
Baseline

Follow up

Baseline

Follow up

100%

% of baseline total adipose area at L3

100
95.4%

95

90

p=0.034
85

80

75

78.8%

Total adipose
area at L3

70

Control
Treatment
0
Baseline

Follow up

100%
100

100%
100

99.4%

90

85

80

75

97.2%
95

94.9%

% of baseline total adipose mass

% of baseline total lean body mass

p<0.001
95

Total lean body mass

70

p=0.04
91.1%

90

85

80

75

Total adipose body mass

70

Control

Control

Treatment
0

Treatment
0

Baseline

Follow up

Baseline

Follow up

FIGURE 5 – Percent change in body composition variables between baseline and follow
up. (Whiskers represent the SEM)
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With regards to the use of medications that can impact body composition (especially
affecting muscularity), 4/22 (18%) of the treated patients used such drugs in the study period
(progestin in three cases and testosterone in one), while 2/44 (4.5%) controls were receiving
those medications (one progestin and one testosterone) (p=0.09). No patients were found to
be under treatment with cannabinoids or corticosteroids in the study period. Among the
treated patients, no difference was found between subjects who received such drugs and
those who did not receive them with regards to total lean body mass [-6.4% (SEM 3.5) vs. 4.8 (SEM 1.4), respectively, p=0.523] and total body fat [-9.9% (SEM 4.2) vs. -8.7 (SEM
2.3), respectively, p=0.58]. Statistical significance was not tested for the control patients due
to the small number of subjects who received the drugs.
A proportion of patients in the control group received oncologic treatment in the study
period (26/44, 59%). Gemcitabine, cisplatin, and oxaliplatin were the most common
chemotherapeutics used. The percent change in total lean body mass was not statistically
different between controls who received and did not receive oncologic treatment [-0.7%
(SEM 0.8) vs. -0.5% (SEM 1.0), respectively, p=0.828]. Similarly, the percent change in
total adipose body mass was not significantly different between controls according to
oncologic treatment during the study period [-4.3% (SEM 1.5) vs. -0.7% (SEM 2.3),
respectively, p=0.179].
The correlations between other potential confounders and variations in body
composition were also analyzed by determining correlations (Table 4). No statistically
significant correlations were observed.
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Age
Time between
advanced cancer to
baseline
Baseline albumin
Performance
status
Number of prior
therapies

Treatment group
Total lean
Total body fat
body mass
mass variation
variation
R
p
R
p
0.27
0.232 -0.41
0.062

Control group
Total lean
Total body fat
body mass
mass variation
variation
R
p
R
p
-0.29
0.79
-0.14
0.372

0.04

0.871

0.19

0.405

-0.05

0.748

0.12

0.423

-0.29

0.195

0.2

0.372

0.14

0.539

-0.21

0.353

-0.19

0.398

0.21

0.345

0.13

0.398

-0.19

0.214

0.21

0.343

0.23

0.306

-0.04

0.79

0.09

0.554

TABLE 4 – Correlations between body composition variation and confounding variables.

Survival analyses
Overall median survival from baseline (95% CI) was of 189 (142-236) days for the
patients treated with curcumin and 299 (240-357) days for the patients in the control group
(log rank p=0.065) (Figure 6). Survival was not significantly different between sarcopenic
and non-sarcopenic patients overall [254 (216-291) vs. 293 (143-443) days, p=0.588].
However, when analyzed separately, the 15 sarcopenic patients in the treatment group
showed significantly shorter survival [169 (115-223) days] in comparison with the 27
sarcopenic patients in the control group [299 (229-369) days, p=0.024], whereas no
difference was found between the survival of the seven non-sarcopenic patients in the
treatment group [254 (216-291)] and the 17 non-sarcopenic control patients [304 (184-423),
p=0.910] (Figure 7).

33

Cumulative survival
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p=0.065

Time (days)
FIGURE 6 – Kaplan-Meier plot: survival from baseline of patients in the treatment (n=22)
and control (n=44) groups.
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FIGURE 7 –Kaplan-Meier plots: survival of sarcopenic and non sarcopenic patients.
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Survival was plotted against changes in body composition between baseline and follow
up for patients in the treatment and control groups whose death was confimed (22/22 and
42/44, respectively) (Figures 8 and 9). The correlation between the variation of total lean
body mass and survival yielded coefficients of 0.283 and -0.035 (p=0.202 and 0.824) for
cases and controls, respectively, whereas the correlation between survival and variation in
total fat body mass yielded coefficients of 0.367 and 0.058 (p=0.09 and 0.713) for cases and
controls, respectively. Even though not statistically significant, shorter survival appeared to
be correlated with greater reductions in body composition parameters only in the group of
patients treated with curcumin.
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FIGURE 8 – Percent change in lean body mass according to survival from baseline. Circles
represent individual patients, solid line the regression line fitted, and dashed lines the 95%CI
band.
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FIGURE 9 – Percent change in adipose body mass according to survival from baseline.
Circles represent individual patients, solid line the regression line fitted, and dashed lines the
95%CI band.
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Exploratory pre-baseline data analyses
Weight data was available for 10/22 (45%) patients in the treatment group and for 17/20
(85%) of their controls. Since one of the treated patients had no controls with prebaseline
weights available, this triad was excluded from comparative prebaseline weight analysis.
Similarly to what was found between baseline and follow up timepoints, the majority of
patients also lost weight between pre-baseline and baseline, with 7/9 (78%) and 15/17 (88%)
patients losing weight in the treatment and control groups, respectively. Figure 10
summarizes the evolution of the body weight (in percentage of the pre-baseline weight). The
variation in percentage of the pre-baseline weight between pre-baseline and baseline time
points was of -2.4% (SEM 1.5) and -1.9% (SEM 1.6) for the treatment and control groups,
respectively (p=0.848) and between baseline and follow up time points it was of -3.1%
(SEM 1.5) and -1.5 (SEM 1.1) of the prebaseline weight for the treatment and control
groups, respectively (p=0.403).

100

100%
98.1%
96.6%
97.6%

% of prebaseline weight

95

94.5%

p=0.829
90

p=0.708
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80

75
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70
0
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Follow up

FIGURE 10 – Percent weight changes at three time points. (Whiskers represent the SEM)
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Treatment responders exploratory analyses
Two patients had significant responses to the previous clinical trial. One of them had
prolonged stable disease for more than 9 months and the other had a significant though short
lived decrease in tumor size [decrease of 73% of the baseline tumor size by RECIST
measurements (124)]. No information was available regarding pre-baseline weights on these
patients. Data regarding weight and body composition for the baseline and follow up time
points are summarized in Table 5. Weight loss in both patients was lower than the average
weight loss for the overall treatment group (3.3%), and the slight increase in total body
adipose mass was a departure from the average reduction of 8.9% in the treatment group.
The patient with partial response had a decrease of total lean body mass greater than the
average decrease of 5.1% in the treatment group, whereas the patient with prolonged stable
disease had a slight increase in this variable.

Partial response patient
Treated Control A Control B
% weight change
from baseline
% lean body mass
change from
baseline
% adipose body
mass from baseline

Stable disease patient
Treated Control A Control B

-1.4%

+1.2%

+4.0%

-0.6%

+3.2%

+4.6%

-7.3%

+3.7%

+5.5%

+0.6%

+5.7%

+5.5%

+0.8%

-3.8%

+6.0%

+0.4%

+1.1%

+6.0%

TABLE 5 – Body composition changes in the responder patients and their controls.
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CHAPTER 6 – DISCUSSION

Curcumin did not seem to reverse nor attenuate body mass losses
The hypothesis for this study was that patients with advanced pancreatic cancer treated
with curcumin for two months have less fat and muscle loss as compared to matched
controls not treated with this compound. In order to evaluate this, the evolution of weight
and body composition was observed in a group of 22 patients who received the drug and 44
controls who did not receive it, matched according to gender, age, time from advanced
cancer diagnosis, body mass index, and number of prior therapies (refer to Table 1 for a
summary of the matching variables).
This study showed that the sample of patients treated with curcumin for two months
lost weight due to both fat and muscle losses, therefore the drug seem to not play a role in
reversing body mass loss in those patients. The weight loss is in line with the previously
described evolution of body composition in populations of patients with pancreatic cancer.
Wigmore et al. showed in a prospective observational study of 20 advanced pancreatic
cancer patients that absolute fat and muscle losses measured by bioelectrical impedance are
significantly different between diagnosis and death (125). Using the same retrospective CT
analysis technique as this study, Tan et al. also described that the majority of patients with
advanced pancreatic cancer lost body mass from both fat and muscle compartments as the
disease evolved (126).
Attenuation of weight loss by curcumin in the setting of pancreatic cancer was
previously described in animal models only. One study in an animal model of cachexia
(MAC16 colon tumor-bearing mice) showed that the administration of a 100mg/kg dose of a
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curcumin complex (curcumin c3, composed of 72% curcumin, 22% desmethoxycurcumin,
and 4% bisdesmethoxycurcumin) was able to attenuate weight loss in the animals (107). In
addition to the fact that animal models frequently do not translate well to human clinical
practice (127), it is of interest to note that the analogue composition of the drug used in the
current study was somewhat different than the used in this animal study (87.2% curcumin,
10% desmethoxycurcumin, and 2.3% bisdesmethoxycurcumin) (104), which might also
contribute for the different findings. Indeed, it appears that each curcumin analogue might
have different activities and potencies, but this is still to be completely determined (128).
Therefore, further research is needed to investigate if distinct curcumin analogues or
combinations can differentially affect body weight. Two other groups, one studying the
effects of curcumin on rats bearing the Yoshida AH-130 ascitis hepatoma cells (which is
known to cause cachexia) (105), and another in mice bearing MAC16 tumor cells (106) did
not show the weight loss attenuation found in the previously described animal study (107).
Interestingly, the latter showed an attenuation of the PIF-induced proteasome expression in
murine myotubes treated with curcumin in vitro (106).
In the present study, both treatment and control groups showed statistically significant
absolute and percent weight losses, with greater losses in the curcumin treated group. The
difference in absolute and percent weight loss was not statistically significant between the
two groups after approximately 2 months. Therefore, our findings do not support the
hypothesis of this study. Of note, the different compartments of body composition, while
consistently decreased, did so in a different fashion between groups.
At baseline, the area of all body compartments measured at L3 (subcutaneous,
intramuscular and visceral fat and skeletal muscle) were similar between groups, as
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therefore were the estimated total lean and adipose body masses (Table 3). At follow up,
significant differences were found when comparing the percent reduction in areas of skeletal
muscle and subcutaneous fat between treated and untreated patients. As expected from these
results, both estimated total lean body mass and total adipose body mass showed
significantly greater reductions in the treatment group (Table 3 and Figure 5). In addition,
patients in the control group lost significantly more adipose tissue than muscle whereas
treated patients lost comparable percentages of muscle and fat.
Efforts are being made towards the creation of a classification of cancer cachexia.
Recently, a preliminary classification of cancer cachexia in three severity degrees
(precachexia, cachexia, and refractory cachexia) was proposed (10). Patients with refractory
cachexia, as the name implies, do not respond to therapies aimed at reversing the process
and invariably undergo a progressive worsening of body composition variables. It might be
that the patients in this study were towards this end of the cachexia spectrum, therefore
being not amenable to reversal of the cachexia process. It is not possible to definitively
identify if the patients in the current study had refractory cachexia, due both to its
retrospective nature and to the lack of a clear and validated definition of the cachexia
severity degrees.
Mounting evidence exists on the potential effects of curcumin in the adipose tissue and
more so in modulation of signal transduction pathways that are paramount for the genesis of
obesity and several of its complications (129). The present study showed that patients with
advanced pancreatic cancer treated with curcumin had significantly greater losses of fat as
compared to matched untreated controls (Figure 5). This might indicate a direct effect of
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curcumin on adiposity which is interesting to be explored in anti-obesity research. Further
research is needed in larger samples of non-cancer patients and healthy individuals.
Sarcopenia (decreased muscle mass) was present at baseline in 68% of the patients who
received curcumin and 61% of the controls, and these prevalences increased at follow up in
both groups, to 82% and 66% for treated and untreated patients, respectively. These figures
are greater than the 51% prevalence that we have shown for a sample of 104 patients with
advanced cancer at our Phase I program (130). This is probably explained by the
heterogeneous population in the previous study. In the setting of pancreatic cancer, the Tan
et al. group reported in a set of 44 patients a proportion of 46% sarcopenic patients at
baseline and of 61% around 135 days later (126). One might interpret that difference as
caused by a selection of patients in a more advanced stage of disease in our study.
Interestingly, however, is that the median overall survival after the baseline image in Tan’s
study is the same as for the patients treated with curcumin in our study (189 days), and
shorter than the median survival for patients in the control group (299 days). Therefore, it is
likely that other factors are in play and affecting the genesis of sarcopenia or survival in our
patients.

Curcumin and survival
In the current study, patients treated with curcumin had median survival from baseline
189 days (95%CI 142-246), 110 days shorter than untreated patients (p=0.065). There are
very few published clinical studies of curcumin in humans, and survival data is scarce.
Epelbaum et al. studied the effects of curcumin combined with gemcitabine for the treatment
of advanced pancreatic cancer in 17 patients and reported a comparable median overall
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survival of 5 months, ranging from 1 to 24 months in the 11 patients who were considered
evaluable (131).
In a retrospective analysis of 83 consecutive pancreatic cancer patients referred to our
Phase I program, it has been shown that they had a median overall survival from referral of
5 months (95%CI 3.3-6.2 months) (132). This is shorter than the results reported here for
both study groups from the baseline image [6.3 months (95%CI 4.7-7.9 months) for patients
treated with curcumin and 10 months (95%CI 8-12 months) for the controls]. For the
patients in the treatment group, the dates of referral to the Phase I program and baseline
image are very similar so it is fair to state that patients who received curcumin had an
overall survival around 1 month longer than the average of referred patients with the same
diagnosis. Of note, patients in the control group had longer overall survival (5 months) than
what was reported for patients with the same diagnosis seen at our Phase I program. This is
of interest because might point out to an unforeseeable selection bias, caused by a systematic
difference between patients referred to phase I and those who were not. It might be that,
regardless of the matching efforts, patients in the control group had better health conditions
at the inception point (time of first image), not being perceived by their physicians as
candidates to the curcumin clinical trial and therefore not referred. This might be
contributing to the difference in overall survival between patients in the treatment and
control groups. In addition, it is important to mention that overall survival is subject to
interference of all treatments undertaken after the inception point, and that more than 50% of
the patients in the control group were receiving oncologic treatment at the time of study
entry and some of the patients in the treatment group received further treatments after being
taken off the curcumin trial. Therefore, it is not possible to ascribe differences in survival
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only to the use of curcumin based solely on the data reported here. This is inherent to the
retrospective design of the current study, despite all matching efforts.
It was also shown in this work that sarcopenic patients treated with curcumin had a
median survival significantly shorter (130 days) than sarcopenic patients in the control
group (Figure 7). Shorter survival in patients with sarcopenia has been previously described
among overweight pancreatic cancer patients (126) and among obese patients with cancers
of the gastrointestinal and respiratory tracts (123). Unfortunately, due to the small number of
patients with combined sarcopenia and overweight/obesity in this study, it was impossible to
conduct survival analyses to explore the influences of this combination of variables in this
patient population. It is of interest that sarcopenic patients treated with curcumin had shorter
survival as compared to untreated patients. Curcumin suffers with low bioavailability issues
(95), and it might be that the differential distribution in the body tissues in sarcopenic
patients had driven a particular action of curcumin in those patients. Further research is
needed to confirm this finding and elucidate the mechanisms by which survival is
significantly reduced when curcumin is used in patients with sarcopenia.
An interesting finding relates to Figures 8 e 9, is the apparent correlation between
percent loss of total lean body mass and total adipose body mass with shorter survival in
patients treated with curcumin. By observing the graphs, it is possible to note that patients
who are closer to death and are receiving curcumin present a greater loss of both total lean
and adipose body masses, while patients in the control group present an almost flat
regression line, denoting that total lean and adipose body mass losses in these patients
remain more stable, regardless of the proximity to death. It seems as if patients who receive
curcumin undergo a metabolic shift towards a more lipolytic weight loss pattern when they
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are towards the end of their lives. It is not possible to determine causality in this
retrospective study, but it is plausible to hypothesize that maybe curcumin is having a direct
effect on the cancer and activating the secretion of LMF (lipid mobilizing factor), for
example. Further research is needed to prove this new hypothesis.

Potential confounders of body composition changes
Changes in body composition might be impacted by several factors. Age, for example,
is well known for being frequently accompanied by fat and muscle loss (133). Performance
status might impact body composition to the extent that it impacts physical conditioning
(134). Considering the very small sample size of the current study, it was not possible to
generate multivariate models to evaluate the participation of potential confounders of the
total adipose and lean body mass variation variables. Therefore, the dyadic correlation
between the potential confounders and each of the body composition percent change
variables was performed to provide preliminary evidence of their independent association
with body composition outcomes (Table 4). Interestingly, the correlation coefficients were
very low and none was statistically significant, pointing towards a small or absent impact of
those potential confounders, when taken independently, on the results of this study.
However, further research in larger samples is needed to evaluate the importance of such
variables in body composition changes in patients with advanced pancreatic cancer.
Medications such as corticosteroids, androgenic steroids, progestins, and cannabinoids
more often than not have a role in the therapeutic arsenal of advanced cancer patients. These
drugs can impact body composition and have to be considered as potential confounders.
Corticosteroids, for example, when used for long periods of time can cause muscle wasting
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(135). Androgenic steroids are capable of decreasing weight loss and/or increase muscle
mass. Nandrolone has been studied in patients with non small cell lung cancer, for example,
and showed lower frequency and intensity of weight loss in patients who received the drug
as opposed to patients who did not receive it (136). In patients with COPD treated with
nandrolone, an increase in fat free muscle mass was shown in comparison with patients
treated with placebo (137). Progestins are the mainstay treatment for cancer cachexia and
have a positive orexigenic effect with some gains in weight (138). In the current study, very
few patients were under treatment with such drugs, and their use was not associated with
differences in body composition.
Patients in the control group could be under oncologic treatments during the study
period, and this is also a potential source of bias since it has been shown in several types of
cancers that the oncologic treatment itself might have an effect on body composition. In
patients with breast cancer, for example, an increase in weight mostly due to fat mass has
been described after oncologic treatment (139). Similar results were described for patients
receiving chemotherapy for Hodgkins lymphoma (140). In the current study, 59% of the
control group was under active oncologic treatment with chemotherapeutic and biologic
anti-cancer agents during the study period. In the control group, no differences were found
with regards to changes in body composition over time when comparing patients according
to presence of absence of oncologic treatment.

Exploratory analyses of the best responders
One important issue regarding the use of curcumin is its very low oral bioavailability in
the currently available formulations (95). Two patients in particular presented interesting
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clinical oncologic responses to the drug in the previous protocol: one had a prolonged stable
disease (more than 9 months) and the other had a 73% tumor reduction that was short lived.
It is plausible that one of the reasons for these patients to respond to the drug is that their
organisms are specially equipped to absorb and adequately utilize curcumin (because of
reasons that are yet to be discovered that might include mutant players in metabolic
pathways, for example). Therefore, analyses of those particular responders were conducted
separately, to evaluate if their body composition changes were particularly different than
that of the majority of the patients on study (Table 5). It was found that both responder
patients lost weight as their non-responder counterparts but on a smaller percent rate,
whereas both gained small amounts of fat mass, a completely different result as compared to
the overall fat loss of almost 9% in the non-responders. Considering this study’s very small
sample, it is impossible to draw definite conclusions about the body composition behavior of
those two patients. In addition, it might be the case that the differences in body composition
changes are reflecting the fact that the patient had an oncologic response and therefore is
progressing differently than the other patients. Whether curcumin is itself having a different
action directly on body composition or the changes in body composition are a consequence
of curcumin action on the cancer is subject for future prospective studies with larger
samples.
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CHAPTER 7 – CONCLUSIONS AND FINAL CONSIDERATIONS

This study was not able to confirm the hypothesis that patients with advanced
pancreatic cancer treated with curcumin for two months have less fat and muscle loss as
compared to matched untreated controls. Both curcumin-treated and untreated patients lost
weight due to a combination of fat and muscle depletion. Curcumin treated patients lost
more weight and had greater losses in all body composition variables. Fat loss was the
prominent feature in both groups, with different adipose compartments behaving differently:
the significant fat loss occurred only in the subcutaneous area. Lean body mass loss also
occurred and was significantly greater in the treated patients.
Overall, patients on curcumin had a borderline significant shorter survival as compared
to their untreated controls, and patients on curcumin with sarcopenia had shorter survivals as
compared to those who did not have sarcopenia.
Additionally, the current study allowed for the rising of some new research hypothesis
such as the possible direct effect of curcumin in the tumor activating the secretion of LMF
and shifting the weight loss from a predominantly proteolytic pattern to a more lipolytic one
in patients towards the end of life.
Some limitations have to be cited for this study. The small sample size and its
retrospective nature impair the ability of drawing definite conclusions. Additionally and also
related to its retrospective characteristic, the study is subject to selection bias, even though
several measures were taken to minimize this risk (1:2 matching by several characteristics,
random selection of controls). However, it is still possible that some remaining systematic
difference between patients treated with curcumin and controls persisted. For example, all
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study subjects had the same diagnosis and were treated at M. D. Anderson Cancer Center at
the same time period. Therefore, it is likely that all of them were treated by a consistent
“pool” of physicians, who sometimes referred the patients to the curcumin clinical trial and
sometimes did not. The choice for referral might have been influenced by several factors,
including the subjective impression of the clinician about the patient’s overall health state. It
might very well be that patients who were considered in better condition were not referred to
the curcumin trial because of the impression that those patients were doing well on current
treatments or could be changed to other therapy lines. This is supported by the finding that
patients in the control group showed an overall survival about five months longer than what
was reported for a group of 83 consecutive patients with advanced pancreatic cancer referred
to our Phase I program. Therefore, it is not impossible that patients in the control group were
in better overall health state (even though not reflected in the matching variables) at the time
of baseline imaging when compared to patients in the treatment group. Unfortunately the
retrospective nature of this study makes it is impossible to precisely quantify the controls’
overall health state at baseline beyond what was already performed by the stringent fivevariable matching procedure.
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